Ashish Kakkar

Leads AI strategy and governance for Indegene Cortex, an enterprise AI knowledge platform for global pharma. Drove release governance, ISO/IEC 42001 readiness, and grew Boehringer Ingelheim account from EUR 600K to EUR 1.2M annually.

Designed clinical safety evaluation framework for oncology AI, achieving 100% safety and 96.3% guideline concordance across 164 consultations. Advised on citation traceability, drug-interaction guardrails, and built commercial model for clinical trials.

Led commercial strategy for Ortho and Gynae portfolios across India, including launches, pricing, and physician engagement. Delivered approximately 35% portfolio growth and rebuilt brand communication.

Launched Exena (Mirabegron), India's first Beta-3 agonist for Overactive Bladder, and managed OAB and OPD portfolios. Led a patient study on diagnosis gaps and adherence that shaped FY18 brand education investment.

Built launch strategy for Imol-P12 R and managed Penegra, Fembio, and Deca-Durabolin. Ran digital patient screening campaigns in men's health.

Managed Gastro, ENT, and Dental portfolios, achieving 38% YoY growth on Urdohep and launching Rifaset.

Conducted market research and brand planning for new cardiovascular launches.

AI Strategy Programme at ISB Hyderabad via Emeritus, ongoing from 2025 to 2026.

MBA in Pharmaceuticals Management from NMIMS School of Business Management, Mumbai, completed in 2014.

Bachelor of Pharmacy from Rajiv Academy for Pharmacy, Mathura, completed in 2012.